UPDATE : Friday, December 13, 2019
상단여백
Ranitidine recall taking heavy toll on pharmaceuticals by Jeong Sae-im 2019-09-30 15:16
Sale of Novartis’ conjunctivitis drug Pataday banned for 3 months by Lee Hye-seon 2019-09-30 11:25
Investor trust in bio-industrialists sank due to latter’s unethical acts by Lee Han-soo 2019-09-27 15:11
Genexine sets up joint firm in Thailand by Lee Han-soo 2019-09-26 17:00
[Analysis] Successive failures throw Korean bioindustry's drug-developing ability into question by Lee Han-soo 2019-09-26 15:39
라인
Pfizer’s leukemia therapy Besponsa to get insurance benefit by Kim Yun-mi 2019-09-26 11:26
'Xtandi emerges as convenient treatment option for prostate cancer patients' by Lee Han-soo 2019-09-25 17:39
Huons, Lipac Oncology to co-develop bladder cancer treatment by Lee Han-soo 2019-09-25 11:18
AstraZeneca releases detailed results of P3 trial of SGLT2 inhibitor by Lee Han-soo 2019-09-24 18:08
Qurient enrolls patients for trials of atopy treatment by Lee Han-soo 2019-09-24 17:00
라인
Hanmi’s US partner to unveil results of anticancer drug study by Lee Han-soo 2019-09-24 17:00
Why using end-to-end services should be part of a drug product strategy by Lee Han-soo 2019-09-24 16:54
Helixmith's fails to end P3 trials of diabetic peripheral neuropathy treatment by Lee Han-soo 2019-09-24 16:38
Hwail, SupexBNP wins patent for neutropenia treatment in US by Lee Han-soo 2019-09-23 22:34
Drug firms uncertain about pricing of quadrivalent flu vaccines by Jeong Sae-im 2019-09-23 14:52
라인
Roche’s Tecentriq becomes 1st immunotherapy to win indication for SCLC by Lee Han-soo 2019-09-23 13:28
‘Diabetes treatment Forxiga born as new heart drug in DAPA-HF study’ by Kim Yun-mi 2019-09-23 11:45
‘Daewoong’s diabetes therapy proves superior blood-sugar-lowering effect to existing drugs’ by Lee Han-soo 2019-09-20 17:51
Dongwha could lose ₩60 billion sales as GSK ends deal by Lee Han-soo 2019-09-20 14:28
Novo Nordisk releases trial result for basal insulin analog injection by Lee Han-soo 2019-09-20 12:27
여백
여백
여백
Back to Top